Navigation Links
Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
Date:8/3/2010

SAN DIEGO, Aug. 3 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology™ based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. Pursuant to the contract, Pfenex will apply its proprietary Pfenex Expression Technology platform to identify high producing expression strains capable of producing high titers of stable rPA.  Pfenex will then leverage its process development and scale up capabilities to develop a cGMP process at commercial production scales and will also evaluate the performance of the protein in IND enabling preclinical studies.  

"We are pleased to be awarded this contract for our rPA development program, which may offer a dramatic improvement in the nation's ability to rapidly produce large amounts of a stable anthrax vaccine at a very competitive cost to the U. S. Government," stated Bertrand C. Liang, Chief Executive Officer,   "A recombinant solution for the production of this strategically relevant product has been sought after for a number of years and we are confident that Pfenex's platform will deliver that solution."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the micro-o
'/>"/>

SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. CRF Health is Awarded for Getting Closer
3. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
4. Zargis Awarded U.S. Army Contract
5. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
6. Sperian Respiratory Protection USA Awarded a 65,000 Reusable Respirator Order by the Veterans Health Administration
7. Sorrento Therapeutics Awarded NIH Grant for MRSA Program
8. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
9. Smith & Nephew Awarded Patient Cleansing and Skin Care Contract with Premier
10. DNA Medicine Institute Awarded NIH Grant for Emergency Point-of-Care Blood Sensor
11. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... has received an AB therapeutic equivalent rating from the ... approved New Drug Application (NDA) for testosterone gel 1.0%. ... to [AbbVie,s] AndroGel 1% and can be substituted with ... clinical effect and safety profile as AndroGel 1% when ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... "Machine Health Monitoring Market by Product, Component, Application ... report to their offering. ... monitoring market is expected to witness a moderate growth ... Europe have almost reached the saturation levels. ...
(Date:7/24/2014)... /PRNewswire-iReach/ -- Delivery of the Report will take ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... survey on Global and Chinese Hemodialysis Machine industry. ... Hemodialysis Machine including its classification, application and manufacturing ... top manufacturers of Hemodialysis Machine listing their product ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
(Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) ... various sub-segments with an in-depth analysis and forecasting ... restraints for this market with insights on trends, ... tables and 36 figures spread through 157 pages ... Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early ...
(Date:7/24/2014)... Amy Norton HealthDay Reporter THURSDAY, ... teenage boy may be dead wrong, according to a small study ... In interviews with 33 boys between the ages of 14 and ... a girl for the closeness and trust. Very few boasted about ... a relationship with a girl. "In our culture, we have ...
(Date:7/24/2014)... Pools and beaches are the place to be ... especially for small children, so Amica Insurance is ... the Centers for Disease Control and Prevention, children between the ... water-related injuries and deaths. It’s important to know the best ... is offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Drinking caffeine ... affect roughly two-thirds of women as they go through ... are preliminary, our study suggests that limiting caffeine intake ... bothersome hot flashes and night sweats," said researcher Dr. ... the Mayo Clinic in Rochester, Minn. But caffeine ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
... Inc. (Nasdaq and SWX: BMRN) today announced that,Jean-Jacques ... a,conference call and webcast on Tuesday, February 26, ... quarter and full year 2007 financial results., ... International Dial-in Number: 617.597.5312 Participant ...
... Present at Merrill Lynch,s Global Pharmaceutical Conference Feb. ... ... today that it will host a conference call and live webcast on,Wednesday, Feb. ... nine months ended Dec. 31, 2007. The Company also will provide,an operational and ...
... Mrs. Bojan M. Kuure, of,Jakobstad, Finland, has ... for her outstanding contributions and achievements in the,field ... About Mrs. Bojan M. Kuure, Mrs. ... a dedicated registered,nurse. She obtained a Special Registered ...
... Feb. 5 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the company expects to initiate shipments of,alendronate sodium ... dosage strengths when,Fosamax(R) loses market exclusivity, which is ... February 6, 2008. Alendronate sodium is the generic,version ...
... Feb. 5 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... cancer, announced today that it will,host a conference ... Time on,Tuesday, February 19, 2008 to discuss the ... A press release will be issued before the ...
... Youth may be more,likely victimized while using instant messenger ... new research this week reports., The study, conducted ... Kids and Kimberly Mitchell of the University of New,Hampshire, ... youth are most likely,to experience sexual solicitation and harassment. ...
Cached Medicine News:Health News:BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET) 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Bojan M. Kuure Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Watson to Distribute Alendronate Tablets 2Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2Health News:Are Social Networking Sites Endangering Young Teens? Study Finds Maybe Not 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: